Rebif (Interferon beta-1a)
( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
13 | 多発性硬化症/視神経脊髄炎 | 10 |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
Showing 1 to 10 of 10 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02921035 (ClinicalTrials.gov) | June 30, 201620160630 | 29/9/201620160929 | Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS) | A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With RMS Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a (MAIN-MS) A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts W ... | Relapsing Multiple Sclerosis (RMS) | Drug: Rebif (Interferon beta-1a) | Merck KGaA, Darmstadt, Germany | Merck Serono Middle East FZ LLC | Completed | 18 Years | 60 Years | All | 594 | Hungary;Iran, Islamic Republic of;Korea, Republic of;Kuwait;Lebanon;Morocco;Poland;Saudi Arabia;Germany;Tunisia;United Arab Emirates;Algeria;Argentina;Bahrain;Bulgaria;Egypt Hungary;Iran, Islamic Republic of;Korea, Republic of;Kuwait;Lebanon;Morocco;Poland;Saudi Arabia;Germ ... | |
2 | NCT02749396 (ClinicalTrials.gov) | May 2, 201620160502 | 20/4/201620160420 | EPID Multiple Sclerosis Pregnancy Study | Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon ß - a Register-based Study in the Nordic Countries Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon ß - a Regis ... | Multiple Sclerosis | Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG;Drug: Extavia (interferon beta-1b), Novartis Pharma AG;Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd;Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd;Drug: Avonex (interferon beta-1a), Biogen Idec Ltd;Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046);Other: No MSDMDs therapy (control) Drug: Betaseron (Interferonbeta-1b, BAY86-5046), Bayer HealthCare AG;Drug: Extavia (interferonbeta-1 ... | Bayer | EPID Research;Biogen;Merck Serono Europe Ltd;Novartis Pharmaceuticals | Completed | N/A | N/A | Female | 2089 | Finland | |
3 | NCT02269930 (ClinicalTrials.gov) | October 201420141000 | 17/10/201420141017 | Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a)and Rebif® (Interfe ... | An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterf ... | Multiple Sclerosis | Drug: peginterferon beta-1a;Drug: Rebif | Biogen Idec | NULL | Completed | 18 Years | 45 Years | Both | 30 | Phase 1 | United States |
4 | NCT01075880 (ClinicalTrials.gov) | May 200920090500 | 24/2/201020100224 | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Mult ... | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated Wi ... | Multiple Sclerosis, Relapsing-Remitting | Drug: Rebif (Interferon beta-1a) | Merck KGaA | Merck spol.s.r.o., Czech Republic | Completed | 18 Years | 65 Years | Both | 300 | N/A | Czech Republic |
5 | NCT00619307 (ClinicalTrials.gov) | July 200720070700 | 8/2/200820080208 | Transition to Rebif New Formulation | A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif® New Formulation From Rebif® (Interferon Beta-1a) With Ibuprofen When Necessary (PRN) or as Prophylaxis A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Rel ... | Relapsing Multiple Sclerosis | Drug: Rebif New Formulation + prophylactic Ibuprofen;Drug: Rebif New Formulation + ibuprofen PRN | Merck KGaA | NULL | Completed | 18 Years | 60 Years | All | 117 | Phase 3 | France;Germany |
6 | EUCTR2006-005972-42-DE (EUCTR) | 20/06/200720070620 | 15/08/200720070815 | A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in rel ... | A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in rel ... | Relapsing multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis Relapsing multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relaps ... | Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA INN or Proposed INN: Interferon beta-1a Other descriptive name: recombinant human IFN beta Trade Name: Ibuprofen Sandoz 400 mg Filmtabletten Product Name: Ibuprofen INN or Proposed INN: Ibuprofen Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA INN or Proposed ... | Merck Serono International SA | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 3 | Germany;France | ||
7 | EUCTR2006-005972-42-FR (EUCTR) | 12/06/200720070612 | 05/04/200720070405 | A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in rel ... | A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in rel ... | Relapsing multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis Relapsing multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relaps ... | Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA | Merck Serono International SA | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 3 | France;Germany | ||
8 | NCT00472797 (ClinicalTrials.gov) | April 200720070400 | 10/5/200720070510 | Rebif New Formulation (RNF) Quality of Life (QOL) Study | A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF) A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measu ... | Relapsing Multiple Sclerosis | Drug: Rebif New Formulation Non Titrated;Drug: Rebif New Formulation Titrated | EMD Serono | NULL | Completed | 18 Years | 60 Years | All | 232 | Phase 3 | United States |
9 | NCT00441103 (ClinicalTrials.gov) | December 200620061200 | 26/2/200720070226 | A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a)in Relapsing Remitting Multiple Scler ... | A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif® New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Mont ... | Multiple Sclerosis, Relapsing-Remitting | Drug: Rebif® New Formulation (IFN-beta-1a, RNF);Drug: Placebo | Merck KGaA | NULL | Completed | 18 Years | 60 Years | All | 180 | Phase 3 | Canada;Germany;Italy;Russian Federation;Spain;Switzerland |
10 | NCT00110396 (ClinicalTrials.gov) | January 200520050100 | 6/5/200520050506 | Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis | A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of R ... | Multiple Sclerosis | Biological: Interferon-beta-1a FBS-free/HSA-free | EMD Serono | Pfizer | Completed | 18 Years | 60 Years | All | 260 | Phase 3 | United States |